Sagimet Biosciences prices $175M underwritten Series A stock offering at $6 to fund acne Phase 3 trial, pipeline
- Offering comprises 29.17 million shares of Series A common stock priced at $6.00 per share.
- Company will prioritize dermatology programs and halt MASH development until non-dilutive funding is secured.
- Plans a U.S. Phase 3 denifanstat acne trial in 2H 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.